Vitrolife AB (CHIX:VITRS) Tariff Resilience Score: 5/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
80 GF Score
Price kr105.75
GF Value kr163.53
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Tariff Resilience Score?

Vitrolife AB CHIX:VITRS 80 Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 80/100 and a GF Value™ of kr163.53 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 835 Medical Devices & Instruments companies, Vitrolife AB ranks better than 79.28% on this metric.

Vitrolife AB has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Vitrolife AB has Vitrolife's medical products face tariff risks in key markets like the US and China. The company has some pricing power and alternative suppliers, but previous tariffs have affected margins.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vitrolife AB might have Average Resilient.

Vitrolife AB  (CHIX:VITRs) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vitrolife AB Tariff Resilience Score Related Terms

CHIX:VITRS vs ABT, SYK, MDT: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Vitrolife AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitrolife AB Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Tariff Resilience Score falls into.


CHIX:VITRS
80GF Score
Vitrolife AB CHIX:VITRS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Vitrolife AB (CHIX:VITRS) has a Tariff Resilience Score of 5 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vitrolife AB ranks #173 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Vitrolife AB's Tariff Resilience Score too high?
Vitrolife AB's current Tariff Resilience Score is 5. Based on the distribution chart, Vitrolife AB ranks #173 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrolife AB has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Tariff Resilience Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #173 out of 835 companies for Tariff Resilience Score. This places Vitrolife AB in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Vitrolife AB's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr163.53, compared to a current price of kr105.75 — trading 35.3% below its estimated fair value. The current Tariff Resilience Score is 5. Vitrolife AB's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr105.75 is trading 35.3% below its estimated GF Value™ of kr163.53. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for CHIX:VITRS:

  • Tariff Resilience Score: 5
  • GF Value™: kr163.53 vs. price of kr105.75 (35.3% below fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
80GF Score

Get the complete analysis for CHIX:VITRS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr105.75
Price
kr163.53
GF Value